Insurers Urge Court To Preserve Cancer Drug Antitrust Suit
By Julia Arciga · January 7, 2021, 4:44 PM EST
Four insurance companies fought back Wednesday against a Bristol-Myers Squibb unit's efforts to stamp out their antitrust lawsuit, claiming they suffered injuries after Celgene sold cancer medicines Thalomid and Revlimid at...
To view the full article, register now.